Advertisement

Topics

Cypress Bioscience Company Profile

12:52 EST 13th November 2018 | BioPortfolio

We are committed to being the innovator and leader in providing products for the treatment of patients with Functional Somatic Syndromes, such as Fibromyalgia Syndrome, or FMS, and other central nervous system disorders. Specifically, our strategy involves acquiring or in-licensing central nervous system, or CNS, active compounds and developing them for novel and typically underserved indications. The term Functional Somatic Syndromes refers to several related syndromes characterized more by symptoms, suffering and disability than by disease specific abnormalities that are found upon physical examination and include many overlapping pain and psychiatric conditions. We find these opportunities in the areas in which the brain and body overlap, where CNS mechanisms have a strong influence on somatic or bodily symptoms, particularly interesting, and our ongoing development program at Cypress, evaluating milnacipran as a potential treatment for FMS, is representative of this strategy. Our goal is to be the first to commercialize a product approved in the United States for the treatment of Fibromyalgia Syndrome, or FMS, the focus of our initial efforts in the area of Functional Somatic Syndromes. In January 2004, we entered into a collaboration agreement with Forest Laboratories, Inc., a leading marketer of central nervous system drugs with a strong franchise in the primary care and psychiatric markets, for the development and marketing of milnacipran. After completing a successful Phase II trial, we commenced the first Phase III trial for milnacipran in October 2003. Enrollment in this trial was completed in December 2004, with results announced in September 2005. In October 2004, Forest Laboratories initiated the second Phase III trial evaluating milnacipran for the treatment of FMS. Additionally, we and Forest commenced our third Phase III trial evaluating milnacipran as a treatment for FMS in the first quarter of 2006. We completed the first pivotal Phase III trial evaluating milnacipran for the treatment of FMS in July of 2005. The Phase III trial was a six month, randomized, placebo-controlled study involving 50 sites and 888 FMS patients who were randomized to either milnacipran treatment or placebo. The preliminary top-line results of the study support the continued development of milnacipran as a treatment for fibromyalgia. Although the results of the trial did not achieve statistical significance at the p<0.05 level, the planned development program for milnacipran, which includes two ongoing Phase III studies, will continue. We obtained an exclusive license for milnacipran from Pierre Fabre Medicament in 2001. Milnacipran has been marketed outside of the United States since 1997 as an antidepressant and has been used by over 3,000,000 patients worldwide. Milnacipran is the first of a new class of agents known as norepinephrine serotonin reuptake inhibitors, or NSRIs, which increase the level of norepinephrine more than they do serotonin. We are continuing to evaluate other various potential strategic transactions, including the potential acquisitions of products, technologies and companies, and other alternatives.

Location

4350 Executive Drive, Suite 325
San Diego
CA
92121
United States of America

Contact

Phone: 619 452 2323
Fax: 619 452 1222
Email: ir-info@cypressbio.com


News Articles [338 Associated News Articles listed on BioPortfolio]

HCA Houston Healthcare completes North Cypress Medical Center acquisition

North Cypress Medical Center is a 139-licensed bed acute care facility in Northwest Houston. The hospital was founded by physicians dedicated to providing their community with a sophisticated, The po...

Arix Bioscience Plc - Arix Bioscience announces first VIPE investment

Arix Bioscience Plc - Arix Bioscience announces first VIPE investment PR Newswire London, August 5 THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF THE EU MARKET ABUSE REGULATIO...

Aytu BioScience, Inc.: Aytu BioScience Announces Pricing of $13.2 Million Underwritten Public Offering

ENGLEWOOD, CO / ACCESSWIRE / October 5, 2018 / Aytu BioScience, Inc. (NASDAQ: AYTU), a specialty pharmaceutical company focused on global commercialization of novel products addressing significant ...

Aytu BioScience, Inc.: Aytu BioScience Announces Closing of $15.2 Million Underwritten Public Offering and Full Exercise of Over-Allotment Option

ENGLEWOOD, CO / ACCESSWIRE / October 10, 2018 / Aytu BioScience, Inc. (NASDAQ: AYTU), a specialty pharmaceutical company focused on global commercialization of novel products addressing significant...

Twist Bioscience Files for $86.3M IPO

Today, Twist Bioscience filed an S-1 with the U.S. Securities and Exchange Commission (SEC), announcing its intent to undergo an initial public offering. The filing shows that Twist intends to raise $...

Aytu BioScience, Inc.: Aytu BioScience Reports 55% Sequential Revenue Growth in Q1 FY19; Adds Tuzistra(R) XR to Portfolio

Company Posts Highest Ever Quarterly Revenue ENGLEWOOD, CO / ACCESSWIRE / November 7, 2018 / Aytu BioScience, Inc. (NASDAQ: AYTU), a specialty pharmaceutical company focused on global commercializa...

Cyclenium Pharma and Haplogen Bioscience Announce Granting of EUREKA Label and Funding to ...

Cyclenium Pharma Inc.Helmut Thomas, Ph.D., DABT, +1-819-571-4296President, CEO & CSOhthomas@cyclenium.comorHaplogen Bioscience GmbHGeorg Casari, Ph.D., +43-1-9165522Chief Exec...

Arix Bioscience Plc - Director/PDMR Shareholding

Arix Bioscience Plc - Director/PDMR Shareholding PR Newswire London, June 11 ARIX BIOSCIENCE PLC Director/PDMR Shareholding Arix Bioscience plc today announces the annual award of nil cost options...

PubMed Articles [68 Associated PubMed Articles listed on BioPortfolio]

DCCN Appoints Dr Brigitte Cypress to the Editorial Board.

Essential oil from Korean Chamaecyparis obtusa leaf ameliorates respiratory activity in Sprague‑Dawley rats and exhibits protection from NF-κB-induced inflammation in WI38 fibroblast cells.

To date, Korean hinoki cypress (Chamaecyparis obtusa), has been widely used for household and commercial purposes. Although the medicinal efficacy of hinoki cypress essential oil has been observed, th...

Efficacy of montelukast as prophylactic treatment for seasonal allergic rhinitis.

The evidence supporting the prophylactic treatment of seasonal allergic rhinitis before the start of pollen dispersal is still lacking. We conducted a study to investigate the efficacy of prophylaxis ...

Improving Undergraduate Life Science Education for the Biosciences Workforce: Overcoming the Disconnect between Educators and Industry.

The BioHealth Capital Region (Maryland, Virginia, and Washington, DC; BHCR) is flush with colleges and universities training students in science, technology, engineering, and mathematics disciplines a...

Youtube for millennial nursing students; using internet technology to support student engagement with bioscience.

Undergraduate nursing programs typically include students with limited 'on-campus' time who need learning resources that are flexible, technologically appropriate, remotely-accessible (mobile smart de...

Clinical Trials [5 Associated Clinical Trials listed on BioPortfolio]

CYPRESS - CYPheR for Evaluating Sustained Safety

CYPRESS: A Prospective,Randomized,Multi-Center,Double-Blind Trial to Assess the Effectiveness and Safety of Different Durations of Dual Anti-Platelet Therapy (DAPT) in Subjects Undergoing ...

Evaluation of 3-V Bioscience-2640 to Reduce de Novo Lipogenesis in Subjects With Characteristics of Metabolic Syndrome

Metabolic syndrome increases the risk for development of heart disease. Another condition associated with metabolic syndrome is fatty liver disease which is also referred to as nonalcoholi...

Pain Relief During Photodynamic Therapy for Actinic Keratoses With a New Irradiation Protocol

This pilot study will try to minimize the pain during exposure to a new red light source (RhodoLED®, Biofrontera Bioscience GmbH, Leverkusen, Germany) used for PDT without compromising it...

Impact of Age on the Prevalence of Allergic Sensitization

Worldwide, respiratory diseases have a significant impact on morbidity and mortality of individuals.Tobacco, lifestyle and certain allergens such as dust mites play an important role in th...

Skin Safety Profile of Different Exposure to the Light Emitting Diode (LED) in Healthy Subjects

Photomodulation is a process which manipulates or regulates cell activity using light sources without thermal effect. Different studies have investigated the use of non-thermal low dose li...

Companies [327 Associated Companies listed on BioPortfolio]

Cypress Bioscience, Inc.

Cypress Bioscience is a pharmaceutical company dedicated to the development of innovative drugs targeting large unmet medical needs for patients suffering from a variety of disord...

Cypress Semiconductor Corp.

Cypress delivers high-performance, mixed-signal, programmable solutions that provide customers with rapid time-to-market and exceptional system value. Cypress offerings include th...

Cypress Pharmaceutical, Inc.

Cypress Pharmaceutical, Inc., founded in 1993, is a specialty pharmaceutical company that develops, markets and distributes generic prescription pharmaceutical products to leading...

Cypress Communications

As one of the nation’s largest providers of managed communication solutions, Cypress supplies the latest in communications technology for small and mid-sized business clients, including advanced dig...

The Idaho Bioscience Association

The Idaho Bioscience Association is a non-profit organization that brings together corporate, academic and political leaders to educate the public and to promote bioscience activities in the state. B...

More Information about "Cypress Bioscience" on BioPortfolio

We have published hundreds of Cypress Bioscience news stories on BioPortfolio along with dozens of Cypress Bioscience Clinical Trials and PubMed Articles about Cypress Bioscience for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Cypress Bioscience Companies in our database. You can also find out about relevant Cypress Bioscience Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Fibromyalgia
FMS (fibromyalgia syndrome) is a widespread idiopathic musculoskeletal pain and fatigue disorder, which is chronic. The pain comes from connective tissues, such as muscles, tendons, and ligaments, but not joints and patients describe it as an ache all ov...

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...

Neurology - Central Nervous System (CNS)
Alzheimer's Disease Anesthesia Anxiety Disorders Autism Bipolar Disorders Dementia Epilepsy Multiple Sclerosis (MS) Neurology Pain Parkinson's Disease Sleep Disorders Neurology is the branch of me...


Corporate Database Quicklinks



Searches Linking to this Company Record